Showing results (171-180 of 302) with videos related to

Sort By:
Pageof 31
Cancer|March 14, 2020
Symptom burden in patients with cancer who are experiencing unplanned hospitalizationRichard A Newcomb, Ryan D Nipp, Lauren P Waldman, et al.
Cancer Chemotherapy and Pharmacology|June 21, 2006
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu, Jeffrey W Clark, David P Ryan, et al.
Cancer|November 1, 2006
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumorsDavid P Ryan, Bert H O'Neil, Jeffrey G Supko, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinomaEileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancerShuji Ogino, Jeffrey A Meyerhardt, Mami Cantor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapyJohn G Gribben, David P Ryan, Richard Boyajian, et al.
Cancer|October 25, 2011
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancerNils D Arvold, David P Ryan, Andrzej Niemierko, et al.
The Oncologist|January 31, 2019
Bridge: Person-Centered Collaborative Care for Patients with Serious Mental Illness and CancerKelly E Irwin, Elyse R Park, Lauren E Fields, et al.
The Oncologist|December 19, 2018
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision AnalysisJin G Choi, Ryan D Nipp, Angela Tramontano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumorsJonathan Goldman, S Gail Eckhardt, Mitesh J Borad, et al.
Pageof 31